Drug Profile
Research programme: hepatitis C virus helicase inhibitors - Vertex Pharmaceuticals
Latest Information Update: 20 Jun 2007
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; RNA helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 07 Apr 2004 This programme is still in active development
- 20 Aug 2001 This programme is still in active development
- 08 Dec 1998 Preclinical development for Hepatitis C in USA (PO)